Download finalist preview

FINALIST PREVI E W
HUYA BIOSCIENCE’S BEST NEW
DRUG AWARD
MANAGEMENT TEAM OF THE YEAR
This Award recognizes excellence in pharmaceutical
development. Launching innovative new products is
the most important function of the industry, and a
successful new drug launch marks the culmination of
years of risky and expensive R&D. The shortlist is:
Scrip’s Management Team of the Year Award will honor
the achievements of management teams whether they
are from the top tier of management at a pharma or
biotech company or a team responsible for specific
operations or projects within a company. The shortlist is:
Bristol-Myers Squibb’s Opdivo (nivolumab)
Opdivo became the first PD-1 immune checkpoint inhibitor to
receive regulatory approval anywhere in the world when it
got the go-ahead in Japan for unresectable melanoma. The US
FDA melanoma approval came later in 2014, and was swiftly
followed by a second approval for metastatic squamous nonsmall cell lung cancer with progression on or after platinumbased chemotherapy.
Clinigen’s Management Team
This is a rapidly growing specialty global pharmaceutical
company with a unique business model of four
complementary divisions. In four years the management team
has driven a six-fold increase in revenues and 17-fold growth
in profits, leading Clinigen from its IPO on AIM in 2012, to
the £225m acquisition of Idis in April 2015 - a deal which
doubled its size overnight and created a global market
leader in the ethical unlicensed supply of medicines.
Merck & Co’s Keytruda (pembrolizumab)
Keytruda is a humanized monoclonal antibody that blocks the
interaction between PD-1 and its ligands, PD-L1 and PD-L2,
releasing the PD-1 pathway-mediated inhibition of the immune
response, including the anti-tumor immune response. It was the
first anti-PD-1 therapy approved in the US and received the FDA’s
Breakthrough Therapy designation for advanced melanoma.
Novartis’s Cosentyx (secukinumab)
This human monoclonal antibody is the first and only
approved IL-17A inhibitor for plaque psoriasis, offering an
important new treatment option, and a better chance of
achieving clear skin. IL-17A plays an important role in the
vicious cycle of psoriasis, signalling skin cells to grow at a
faster rate and build up on the skin’s surface, and at the same
time, triggering itching and redness.
Otsuka’s Jinarc (tolvaptan)
Jinarc is the first and only disease-modifying treatment proven
to slow the progression of autosomal dominant polycystic
kidney disease (ADPKD). It is a potent vasopressin receptor
antagonist that reduces the growth rate of renal cysts through
V2 receptor antagonism so that the increase in kidney size
typically observed in ADPKD is slowed, helping to decrease
the rate of kidney function decline.
PTC Therapeutics’ Translarna (ataluren)
In August 2014, PTC Therapeutics’ Translarna became the
world’s first approved drug to treat an underlying cause
of Duchenne muscular dystrophy, a rare and fatal genetic
disease. The orally bioavailable small molecule is designed to
enable the formation of a functioning protein in patients with
genetic disorders caused by a nonsense mutation.
SPONSORED BY
SPONSORED BY
Sponsored by Covance
Horizon Discovery’s Management Team
This team has led the company through a transformational
year post its IPO in March 2014 to firmly establish it as a
world-leading translational genomics company. The firm
has transitioned from a newly listed AIM company with 80
employees located in a single facility in Cambridge, to an
international life science group employing approaching
250 employees in the UK, US, and Austria, and grown its
customer base and revenues.
Marathon Pharmaceuticals’ Management Team
This team, formed more than a decade ago at Ovation
Pharmaceuticals, launched Marathon to continue working to
bring new rare-disease treatments to patients after Ovation
was acquired by Lundbeck. Adding to its achievements
developing or keeping on the market drugs for a range of
orphan drugs, it has successfully advanced its development
pipeline and earned Fast-Track status for deflazacort as a
potential treatment for Duchenne muscular dystrophy.
Sunovion Pharmaceuticals’ Global Clinical Development
Management Team
Taking “Together as One” as its mantra, this matrix-model
team of R&D professionals from Sunovion in the US, Canada,
and Europe along with colleagues from parent company
Sumitomo Dainippon Pharma has realized its vision of
globalized clinical development. The team has followed
strategic and cultural initiatives recognized internally for
driving global collaboration in trials conducted in multiple
countries, using coordinated plans and strategies, and
harmonized processes across geographies.
SPONSORED BY
SPONSORED
BY
SOCIAL MEDIA
SPONSOR
SOCIAL
MEDIA
SOCIAL MEDIA
SPONSOR
SPONSOR